StockWatch
·
Q1 FY-2027 RESULTS · LESL

Leapfrog Engineering's maiden FY26: PAT up 21% to ₹19.6 Cr, margins widen

PAT +20.7% YoY · revenue +13.1% · margins expanding

Q1 FY27 resultsLESLLeapfrog Engineering Services Ltd13 Jul 2026 · 3 min read
Revenue

₹152.34 Cr

+13.1% YoY

PAT (standalone)

₹19.58 Cr

+20.7% YoY

Net margin

11.98%

EPS

₹1.83

Leapfrog Engineering Services — a Bengaluru EPC/engineering-services firm that listed on the BSE SME platform in June 2026 — posted its first audited results as a public company: FY26 standalone revenue of ₹152.34 Cr (+13.1% YoY from ₹134.66 Cr) and net profit of ₹19.58 Cr (+20.7% YoY from ₹16.22 Cr), with the auditor (GRSM & Associates) issuing an unmodified opinion. Profit grew faster than revenue because margins expanded on every line: PBT rose 25.3% to ₹27.39 Cr (PBT margin 18.0% vs 16.2%) and net margin widened to 12.9% from 12.0%. There were no exceptional or extraordinary items on either side — the growth is fully operational, so reported and adjusted YoY are the same.

The scoreboard

Q1 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹152.34 Cr
Expenses₹136.09 Cr
PAT₹19.58 Cr+20.7%
Net margin11.98%
EPS₹1.83

No year-ago quarter on record — YoY cells may be blank.

The headline masks a heavily back-ended year: H2 FY26 (Oct 2025–Mar 2026) alone delivered ₹113.97 Cr of revenue and ₹13.49 Cr of PAT — roughly 75% of the full-year topline — against just ₹38.37 Cr / ₹6.10 Cr in H1. Sequential 'growth' is therefore a seasonality artifact of project-execution timing, not momentum, and should not be read as acceleration. Two cautionary threads sit under the clean P&L: trade receivables of ₹107.07 Cr (~70% of annual revenue) and short-term borrowings up to ₹31.33 Cr pushed operating cash flow to negative ₹5.04 Cr for the year despite a ₹27.4 Cr PBT — cash conversion, not profitability, is the pressure point.

Beyond the headline

What the summary numbers don't show

Maiden result since the June-2026 BSE-SME IPO (₹79.6 Cr raised at ₹23/share, face value ₹1); no analyst coverage or prior guidance on record.

There is no street consensus or management guidance to measure against: Simply Wall St shows zero analyst coverage, appropriate for a company listed weeks ago. The IPO prospectus cited a ₹384 Cr order book, and in early July 2026 (post-period) the company disclosed fresh wins — a ₹4.54 Cr Cotmac order and a ~₹60 Cr ($7.2M) Oman contract — which, with a 6.37% stake bought by Deep Health AI in June, form the demand backdrop for FY27. This is a solid, clean double-digit-growth print; the test next year is whether the order book converts and whether receivables are collected.

What to watch

  • W1

    Order conversion: whether the July-2026 wins (~₹60 Cr Oman + ₹4.54 Cr Cotmac) and the ₹384 Cr IPO order book translate to FY27 revenue.

  • W2

    Receivables/cash discipline: trade receivables at ₹107.07 Cr (~70% of FY26 revenue) drove operating cash flow to -₹5.04 Cr — the key swing factor to verify next period.

  • W3

    H2 seasonality repeat: H1 ran at just ₹38.37 Cr revenue / ₹6.10 Cr PAT — the first post-listing half will test how back-ended FY27 remains.

Clean digital PDF, headers unambiguous, all arithmetic ties (163.48=152.34+11.14; 19.58=27.39-7.81; tax=current 7.86Cr + deferred -0.05Cr). NO exceptional/extraordinary items on either side. PERIOD MISMATCH: expected Q1 FY27 but filing is FY26 annual + H2 FY26 audited (first result after June-2026 BSE-SME IPO). No consolidated section. Heavily H2-weighted: H2 revenue 113.97Cr = 75% of full year. Operating cash flow was NEGATIVE (-5.04Cr) despite 27.4Cr PBT, driven by receivables build.

Informational and educational content only. Not investment advice.